Inovio Pharmaceuticals stock has November 9 earnings date

Published on 10/15/2026 at 22:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash was USD 31.53 million on June 30, 2026. Inovio Pharmaceuticals stock costs EUR 0.92 on October 15, 2026, up 5.05 percent on Nasdaq.

Upcoming results and market figures

Inovio Pharmaceuticals is expected to report earnings on November 9, 2026.
Cash and cash equivalents stood at USD 31.53 million on June 30, 2026.
Inovio Pharmaceuticals stock costs EUR 0.92 at Lang & Schwarz on October 15, 2026 at 10:35 p.m. CEST, up 5.05 percent on Nasdaq.
Market capitalization stood at USD 71.9 million on October 15, 2026.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals stock has an expected earnings date of November 9, 2026, according to Zacks. At Lang & Schwarz, the stock was trading at EUR 0.92 on October 15, 2026 at 10:35 p.m. CEST, while the Nasdaq quote was up 5.05 percent on the day.

Cash and clinical evidence

Cash and cash equivalents stood at USD 31.53 million on June 30, 2026. That balance provides a concrete financial marker ahead of the next scheduled earnings report.

INOVIO says 72 percent of patients in its Phase 1/2 RRP-001 trial achieved a 50 to 100 percent reduction in surgeries during the first year, according to INOVIO. The company is developing DNA medicines for cancer, infectious disease and HPV-related conditions.

Price position after hours

The Nasdaq quote was USD 1.04 at 4:00 p.m. ET on October 15, 2026, compared with a USD 0.99 prior close. The 52-week range was USD 0.56 to USD 2.72, putting the latest home-market price 61.76 percent below the high.

Lang & Schwarz showed a bid of EUR 0.90 and an ask of EUR 0.94 at 10:35 p.m. CEST. The euro quotation therefore remained below the EUR 1.00 mark during the after-hours phase.

Valuation and November date

Inovio had a market capitalization of USD 71.9 million on October 15, 2026. Its price-to-earnings ratio was negative 0.89, while trading volume reached 1,757,181 shares against an average volume of 4,052,368 shares.

Zacks lists November 9, 2026 as the estimated next earnings release date and expects adjusted earnings per share of negative USD 0.20 for the quarter ending in September 2026.

Comparison with peers

INO: plus 5.05 percent, price-to-earnings ratio negative 0.89, market capitalization USD 71.9 million.

Intellia Therapeutics (Nasdaq, USD): minus 0.79 percent, price-to-earnings ratio negative 3.38, market capitalization USD 1.6 billion.

Moderna (Nasdaq, USD): plus 4.51 percent, price-to-earnings ratio negative 29.64, market capitalization USD 94.4 billion.

After-hours trading stays in view

The next earnings date is the clearest scheduled marker for the stock. The company combines a USD 31.53 million cash balance with a clinical pipeline whose trial data remain central to its valuation.

Inovio Pharmaceuticals stock was trading at EUR 0.92 at Lang & Schwarz on October 15, 2026 at 10:35 p.m. CEST, with a bid of EUR 0.90 and an ask of EUR 0.94. The further course of trading is shown by the continuously updated real-time quote of Inovio Pharmaceuticals stock.